Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) EBITDA: 2020-2025

Historic EBITDA for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $215.9 million.

  • Apellis Pharmaceuticals' EBITDA rose 477.27% to $215.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.7 million, marking a year-over-year increase of 118.13%. This contributed to the annual value of -$197.6 million for FY2024, which is 62.80% up from last year.
  • Apellis Pharmaceuticals' EBITDA amounted to $215.9 million in Q3 2025, which was up 618.13% from -$41.7 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' 5-year EBITDA high stood at $215.9 million for Q3 2025, and its period low was -$219.4 million during Q2 2021.
  • For the 3-year period, Apellis Pharmaceuticals' EBITDA averaged around -$58.8 million, with its median value being -$66.4 million (2024).
  • Per our database at Business Quant, Apellis Pharmaceuticals' EBITDA tumbled by 285.23% in 2021 and then skyrocketed by 477.27% in 2025.
  • Apellis Pharmaceuticals' EBITDA (Quarterly) stood at -$148.0 million in 2021, then declined by 10.69% to -$163.8 million in 2022, then surged by 44.43% to -$91.1 million in 2023, then spiked by 59.89% to -$36.5 million in 2024, then surged by 477.27% to $215.9 million in 2025.
  • Its last three reported values are $215.9 million in Q3 2025, -$41.7 million for Q2 2025, and -$92.0 million during Q1 2025.